{"entity":{"id":"nct07637513","kind":"trial","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","aka":["PrE0512"],"tldr":"A phase 3 trial of tarlatamab and durvalumab in lung cancer, run by PrECOG, LLC., not yet recruiting.","summary":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07637513 by PrECOG, LLC., with a registry enrolment figure of 430 participants, started 2027-01 and due to reach its primary completion in 2037-11. Interventions recorded: Tarlatamab; Durvalumab. Conditions listed: Limited Stage Small-Cell Lung Cancer. Primary outcome: This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).; This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).. Lung eligibility wording from the registry: \"* Patient must have histologically or cytologically confirmed Small Cell Lung Cancer (SCLC)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07637513","url":"https://clinicaltrials.gov/study/NCT07637513"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["limited-stage-sclc"],"sections":[],"technologies":["bispecific-antibody","checkpoint-inhibitor","t-cell-engager"],"targets":[],"drugs":["tarlatamab","durvalumab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07637513","phase":"3","setting":"Phase III Trial of Consolidation Tarlatamab + Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC)","sponsor":"PrECOG, LLC.","enrolled":430,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07637513/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}